US6306894B1 - Injectable composition - Google Patents
Injectable composition Download PDFInfo
- Publication number
- US6306894B1 US6306894B1 US09/563,969 US56396900A US6306894B1 US 6306894 B1 US6306894 B1 US 6306894B1 US 56396900 A US56396900 A US 56396900A US 6306894 B1 US6306894 B1 US 6306894B1
- Authority
- US
- United States
- Prior art keywords
- composition
- paclitaxel
- pharmaceutical
- acid
- matter according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
Definitions
- This invention relate to a solution of paclitaxel having improved stability.
- Paclitaxel is a compound extracted from the bark of a western yew, Taxus brevifolia and known for its antineoplastic activity. It is described for example in The Merck Index, Eleventh Edition 1989, monograph 9049.
- paclitaxel was chosen for development as an antineoplastic agent because of its unique mechanism of action and good cytotoxic activity against IP implanted D16 melanoma and the human X-1 mammary tumor xenograft.
- Paclitaxel is believed to function as a mitotic spindle poison and as a potent inhibitor of cell replication in vitro.
- Other mitotic spindle points (colchicine and podophyllotoxin) inhibit microtubule assembly.
- Paclitaxel employs a different mechanism of action since it appears to shift the equilibrium of polymerimization/depolymerization toward polymer assembly and to stabilize microtubules against depolymerization under conditions which would cause rapid disaggregation of microtubules.
- the interference with the polymerization/depolymerization cycle in cells appears to interfere with both the replication and migration of cells.
- paclitaxel After extensive preclinical screening in mouse tumor models, paclitaxel entered clinical trials in 1983. Over the past few years, paclitaxel has demonstrated good response rates in treating both ovarian and breast cancer patients who were not benefitting from vinca alkaloid or cisplatin therapy. It has also shown encouraging results in patients with other types of cancer including lung, melanoma, lymphoma, head and neck.
- the invention provides a solution containing paclitaxel, cremophor ELTM and ethanol, characterized in that the pH of the solution has been adjusted into the range 1 to 8 by addition of an acid.
- Acids in the form of powders for example citric acid
- those which contain water for example sulfuric acid.
- the most preferred acid for use in accordance with the present invention is citric acid, but a wide range of acids may be used including the following:
- Citric acid monohydrous
- Paclitaxel is usually prepared and administered in a vehicle containing cremophor ELTM (a polyethoxylated castor oil which acts as a solubilizer) and ethanol.
- cremophor ELTM a polyethoxylated castor oil which acts as a solubilizer
- BMS Bristol-Myers Squibb
- the invention essentially teaches addition of an acid to a paclitaxel formulation to adjust its pH into the range 1 to 8, preferable 5 to 7.
- Citric acid was dissolved in absolute alcohol, using a ratio of 8 mls of absolute alcohol to 1 gram of citric acid, and the solution was stirred for fifteen (15) minutes.
- Cremophor EL was weighed out into the main mixing vessel.
- Solution 1 was added to solution 2, and the container used for solution 2 was washed with a minimum quantity of absolute alcohol to ensure complete transfer of the citric acid.
- Solution 3 was mixed and bubbled with nitrogen for at least 15 minutes.
- the paclitaxel was weighed out and slurried using absolute alcohol, using a ratio of 8 ml of absolute alcohol to 1 gm of paclitaxel.
- the slurried paclitaxel was added to solution 3 and the slurrying vessel was washed with a minimum quantity of absolute alcohol.
- Solution 3 was adjusted to 75% of required volume using absolute alcohol, and thoroughly stirred for at least 45 minutes until completely dissolved. Once completely dissolved, the volume was checked and made up as necessary with absolute alcohol and the final solution stirred for 5 minutes.
- Cremophor EL 0.5 mL Citric Acid (Anhydrous) 2.0 mg Paclitaxel 6.0 mg Absolute Alcohol to 1.0 mL
- the solutions were filled into clear type 1 glass 5 mL vials and sealed with rubber bungs.
- the solution was filled into clear type I glass 5 mL vials and sealed with rubber bungs.
- the solution was stored at 40° C. for 7 days.
Abstract
A pharmaceutical formulation of paclitaxel and polyethoxylated castor oil is disclosed to be relatively acidified to a pH of less than 8.1 and preferably within a pH range of 5 to 7, inclusively. Ethanol is optionally included in the formulation which is adapted for use in a body for the treatment of cancer. A formulation method is disclosed and includes the step of mixing an acid with a carrier material, such as polyethoxylated castor oil, to form a carrier solution after which paclitaxel is added in an amount such that the resulting pH is less than 8.1 and preferably in a pH range of 5 to 7. Ethanol may optionally be slurried with the paclitaxel before mixing with the carrier solution. A variety of acidifying agents, a preferred one being anhydrous citric acid, are described.
Description
This application is a continuation of U.S. Ser. No. 09/356,158, filed Jul. 19, 1999, now U.S. Pat. No. 6,140,359, which is a continuation of U.S. Ser. No. 08/979,836, filed Nov. 26, 1997, now U.S. Pat. No. 5,977,164, which is a divisional of U.S. Ser. No. 08/594,478, filed Jan. 31, 1996, now U.S. Pat. No. 5,733,888; which is a continuation of U.S. Ser. No. 07/995,501, filed Dec. 22, 1992, now abandoned.
This invention relate to a solution of paclitaxel having improved stability.
This application claims priority under 35 USC 119 to Australian Patent No. 6074 filed Nov. 27, 1992.
Paclitaxel is a compound extracted from the bark of a western yew, Taxus brevifolia and known for its antineoplastic activity. It is described for example in The Merck Index, Eleventh Edition 1989, monograph 9049.
In 1977, paclitaxel was chosen for development as an antineoplastic agent because of its unique mechanism of action and good cytotoxic activity against IP implanted D16 melanoma and the human X-1 mammary tumor xenograft. Paclitaxel is believed to function as a mitotic spindle poison and as a potent inhibitor of cell replication in vitro. Other mitotic spindle points (colchicine and podophyllotoxin) inhibit microtubule assembly. Paclitaxel employs a different mechanism of action since it appears to shift the equilibrium of polymerimization/depolymerization toward polymer assembly and to stabilize microtubules against depolymerization under conditions which would cause rapid disaggregation of microtubules. The interference with the polymerization/depolymerization cycle in cells appears to interfere with both the replication and migration of cells.
After extensive preclinical screening in mouse tumor models, paclitaxel entered clinical trials in 1983. Over the past few years, paclitaxel has demonstrated good response rates in treating both ovarian and breast cancer patients who were not benefitting from vinca alkaloid or cisplatin therapy. It has also shown encouraging results in patients with other types of cancer including lung, melanoma, lymphoma, head and neck.
For further information, reference may be made to the U.S. National Cancer Institute's Clinical Brochure for Taxol, revised July 1991, and papers presented at the Second National Cancer Institute Workshop on Taxol and Taxus held in Alexandria, Va. USA on Sep. 23-24, 1992.
It is a disadvantage of the known formulation that the paclitaxel therein degrades, with the result that the shelf life of the formulation is unsatisfactory, and there is therefore a need for a paclitaxel solution of improved stability.
Accordingly, in a general aspect the invention provides a solution containing paclitaxel, cremophor EL™ and ethanol, characterized in that the pH of the solution has been adjusted into the range 1 to 8 by addition of an acid.
Acids in the form of powders, for example citric acid, are preferred over those which contain water, for example sulfuric acid. The most preferred acid for use in accordance with the present invention is citric acid, but a wide range of acids may be used including the following:
Citric acid—monohydrous
Citric acid—anhydrous
Citric acid—hydrous
Acetic acid
Formic acid
Ascorbic acid
Aspartic acid
Benzene sulphonic acid
Benzoic acid
Hydrochloric acid
Sulphuric acid
Phosphoric acid
Nitric acid
Tartaric acid
Diatrizoic acid
Glutamic acid
Lactic acid
Maleic acid
Succinic acid
Due to its limited solubility in water, Paclitaxel is usually prepared and administered in a vehicle containing cremophor EL™ (a polyethoxylated castor oil which acts as a solubilizer) and ethanol. A commercially available solution supplied by Bristol-Myers Squibb (BMS) is formulated with these components and has a pH of 9.1.
As indicated above, the invention essentially teaches addition of an acid to a paclitaxel formulation to adjust its pH into the range 1 to 8, preferable 5 to 7.
In a preferred procedure adopted by the applicant, which it will be clearly understood is non-limiting, the following steps were carried out:
Mixing Instructions
Solution 1
Citric acid was dissolved in absolute alcohol, using a ratio of 8 mls of absolute alcohol to 1 gram of citric acid, and the solution was stirred for fifteen (15) minutes.
Solution 2
Cremophor EL was weighed out into the main mixing vessel.
Solution 3
Solution 1 was added to solution 2, and the container used for solution 2 was washed with a minimum quantity of absolute alcohol to ensure complete transfer of the citric acid. Solution 3 was mixed and bubbled with nitrogen for at least 15 minutes. The paclitaxel was weighed out and slurried using absolute alcohol, using a ratio of 8 ml of absolute alcohol to 1 gm of paclitaxel. The slurried paclitaxel was added to solution 3 and the slurrying vessel was washed with a minimum quantity of absolute alcohol. Solution 3 was adjusted to 75% of required volume using absolute alcohol, and thoroughly stirred for at least 45 minutes until completely dissolved. Once completely dissolved, the volume was checked and made up as necessary with absolute alcohol and the final solution stirred for 5 minutes.
A solution was prepared with the following formulation:
Cremophor EL | 0.5 | mL | ||
Citric Acid (Anhydrous) | 2.0 | mg | ||
Paclitaxel | 6.0 | mg | ||
Absolute Alcohol | to 1.0 | mL | ||
The pH of this solution was determined as 6.1.
The stability of this sample was compared with a sample prepared by the formulation stated in the NCI Taxol Clinical brochure (as follows) which had a pH of 9.1. (Sample 2)
Sample 2 | per mL | |||
Paclitaxel | 6 | mg | ||
Cremophor EL | 0.5 | mL | ||
Absolute Alcohol | to 1 | mL | ||
The solutions were filled into clear type 1 glass 5 mL vials and sealed with rubber bungs.
The solutions were stored at 40° C. for 7 (seven) days and the stability results are shown in Table 1.
Sample 1 | Sample 2 | ||
pH | 6.2 | 9.0 | ||
Potency | 96.6 | 86.7 | ||
Major individual impurity | 0.3% | 5.1% | ||
Total impurities | 1.0% | 12.2% | ||
Clearly Sample 1 showed significantly increased stability over Sample 2.
A solution was prepared with the following formulation:
Cremophor EL | 0.5 | mL | ||
Paclitaxel | 6.0 | mg | ||
Absolute Ethanol | to 1.0 | mL | ||
The solution was filled into clear type I glass 5 mL vials and sealed with rubber bungs.
The solution was stored at 40° C. for 7 days.
The stability results obtained are compared to those seen with Sample 2.
Sample 1 | Sample 2 | ||
pH | 6.7 | 9.0 | ||
Potency | 97.5 | 86.7 | ||
Major individual impurity | 0.3% | 5.1% | ||
Total impurities | 2.3% | 12.2% | ||
Again the significantly superior stability of the formulation according to the invention (Sample 3) is evident.
It will be clearly understood that the invention in its general aspects is not limited to the specific details referred to hereinabove.
Claims (38)
1. A composition of matter comprising a sealable container and a pharmaceutical formulation contained therein; said pharmaceutical formulation comprising paclitaxel, a pharmaceutically-acceptable carrier, and an acid, said formulation being such that at least 95% of the paclitaxel potency is retained when said formulation is stored at 40° C. for seven days; and wherein said pharmateutical formulation has been sealed in said container for at least seven days.
2. A composition of matter produced by the process of:
a) obtaining a sealable container;
b) obtaining a pharmaceutical formulation comprising paclitaxel, a pharmaceutically-acceptable carrier, and an acid, said formulation being such that at least 95% of the paclitaxel potency is retained when said formulation is stored at 40° C. for seven days;
c) placing said pharmaceutical formulation in said sealable container;
d) sealing said sealable container; and
e) storing said pharmaceutical formulation in said sealed container for at least seven days.
3. A composition of matter according to claim 1, wherein said pharmaceutical formulation has a pH between 5 and 7, inclusive.
4. A composition of matter according to claim 1, further comprising ethanol as a constituent thereof.
5. A composition of matter according to claim 4, wherein said pharmaceutical formulation has a pH between 5 and 7, inclusive.
6. A composition of matter according to claim 1, wherein said pharmaceutically acceptable carrier is polyethoxylated castor oil.
7. A composition of matter according to claim 1, wherein said pharmaceutical formulation is anhydrous.
8. A composition of matter according to claim 6, wherein said acid is a mineral acid.
9. A composition of matter according to claim 6, wherein said acid is an organic acid.
10. A composition of matter according to claim 6, wherein said acid is acetic acid.
11. A composition of matter according to claim 6, wherein said acid is citric acid.
12. A composition of matter according to claim 11, wherein said citric acid is anhydrous.
13. A composition of matter according to claim 2, wherein said pharmaceutical formulation has a pH between 5 and 7, inclusive.
14. A composition of matter according to claim 2, further comprising ethanol as a constituent thereof.
15. A composition of matter according to claim 14, wherein said pharmaceutical formulation has a pH between 5 and 7, inclusive.
16. A composition of matter according to claim 2, wherein said pharmaceutically acceptable carrier is polyethoxylated castor oil.
17. A composition of matter according to claim 2, wherein said pharmaceutical formulation is anhydrous.
18. A composition of matter according to claim 16, wherein said acid is a mineral acid.
19. A composition of matter according to claim 16, wherein said acid is an organic acid.
20. A composition of matter according to claim 16, wherein said acid is acetic acid.
21. A composition of matter according to claim 16, wherein said acid is citric acid.
22. A composition of matter according to claim 21, wherein said citric acid is anhydrous.
23. A method of formulating a pharmaceutical paclitaxel composition such that the paclitaxel does not readily degrade, comprising the following steps:
mixing paclitaxel with a pharmaceutically acceptable carrier material to form a pharmaceutical paclitaxel composition, the pH of said carrier material having been reduced to a level such that when paclitaxel is mixed therewith at least 95% of the paclitaxel potency is retained when the composition is stored at 40° C. for seven days;
sealing said pharmaceutical paclitaxel composition in a sealable container; and
storing said pharmaceutical paclitaxel composition in said sealed container for at least seven days.
24. A method according to claim 23, wherein said pharmaceutically acceptable carrier material comprises polyethoxylated castor oil.
25. A method according to claim 23, wherein said pharmaceutical paclitaxel composition is anhydrous.
26. A method according to claim 24, wherein said pharmaceutical paclitaxel composition also comprises ethanol.
27. An article of manufacture comprising a container and a pharmaceutical formulation contained therein, said pharmaceutical formulation comprising a pharmaceutically acceptable carrier and paclitaxel, wherein the pH of said pharmaceutically acceptable carrier has been reduced to a level such that at least 95% of the potency of paclitaxel added thereto is retained when the pharmaceutical formulation is stored at 40° C. for seven days.
28. An article of manufacture according to claim 27, wherein said pharmaceutically acceptable carrier comprises polyethoxylated castor oil.
29. An article of manufacture according to claim 28, wherein said pharmaceutical formulation is anhydrous.
30. An article of manufacture according to claim 28, wherein said pharmaceutical formulation further comprises ethanol.
31. A method of making a pharmaceutical paclitaxel composition, comprising the steps of:
obtaining a pharmaceutically acceptable carrier material;
reducing the pH of said carrier material to a level such that when paclitaxel is mixed therewith, at least 95% of the paclitaxel potency is retained when the resulting composition is stored at 40° C. for seven days;
mixing paclitaxel with said reduced-pH carrier material to form a pharmaceutical paclitaxel composition;
sealing said pharmaceutical paclitaxel composition in a sealable container; and
storing said pharmaceutical paclitaxel composition in said sealed container for at least seven days.
32. A method according to claim 31, wherein said pharmaceutically acceptable carrier material comprises polyethoxylated castor oil.
33. A method according to claim 32 wherein said pharmaceutical paclitaxel composition is anhydrous.
34. A method according to claim 31, wherein said pharmaceutical paclitaxel composition further comprises ethanol.
35. A composition of matter produced by the process of:
obtaining a pharmaceutically acceptable carrier material;
reducing the pH of said carrier material to a level such that when paclitaxel is mixed therewith, at least 95% of the paclitaxel potency is retained when the resulting composition is stored at 40° C. for seven days;
mixing paclitaxel with said reduced-pH carrier material to form a pharmaceutical paclitaxel composition;
sealing said pharmaceutical paclitaxel composition in a sealable container; and
storing said pharmaceutical paclitaxel composition in said sealed container for at least seven days.
36. A composition of matter according to claim 35 wherein said pharmaceutically acceptable carrier material comprises polyethoxylated castor oil.
37. A composition of matter according to claim 36, wherein said pharmaceutical paclitaxel composition is anhydrous.
38. A composition of matter according to claim 35, wherein said pharmaceutical paclitaxel composition further comprises ethanol.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/563,969 US6306894B1 (en) | 1992-11-27 | 2000-05-03 | Injectable composition |
US09/970,558 US6770670B2 (en) | 1992-11-27 | 2001-10-04 | Injectable composition |
US10/835,875 US20040204479A1 (en) | 1992-11-27 | 2004-04-29 | Injectable composition |
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU6074 | 1984-07-18 | ||
AUPL607492 | 1992-11-27 | ||
US99550192A | 1992-12-22 | 1992-12-22 | |
US08/594,478 US5733888A (en) | 1992-11-27 | 1996-01-31 | Injectable composition |
US08/979,836 US5977164A (en) | 1992-11-27 | 1997-11-26 | Stabilized pharmaceutical composition |
US09/356,158 US6140359A (en) | 1992-11-27 | 1999-07-19 | Injectable composition |
US09/563,969 US6306894B1 (en) | 1992-11-27 | 2000-05-03 | Injectable composition |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/356,158 Continuation US6140359A (en) | 1992-11-27 | 1999-07-19 | Injectable composition |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/970,558 Continuation US6770670B2 (en) | 1992-11-27 | 2001-10-04 | Injectable composition |
Publications (1)
Publication Number | Publication Date |
---|---|
US6306894B1 true US6306894B1 (en) | 2001-10-23 |
Family
ID=25644377
Family Applications (7)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/594,478 Expired - Lifetime US5733888A (en) | 1992-11-27 | 1996-01-31 | Injectable composition |
US08/979,836 Expired - Lifetime US5977164A (en) | 1992-11-27 | 1997-11-26 | Stabilized pharmaceutical composition |
US09/028,906 Expired - Lifetime US5972992A (en) | 1992-11-27 | 1998-02-24 | Injectable composition |
US09/356,158 Expired - Fee Related US6140359A (en) | 1992-11-27 | 1999-07-19 | Injectable composition |
US09/563,969 Expired - Fee Related US6306894B1 (en) | 1992-11-27 | 2000-05-03 | Injectable composition |
US09/970,558 Expired - Fee Related US6770670B2 (en) | 1992-11-27 | 2001-10-04 | Injectable composition |
US10/835,875 Abandoned US20040204479A1 (en) | 1992-11-27 | 2004-04-29 | Injectable composition |
Family Applications Before (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/594,478 Expired - Lifetime US5733888A (en) | 1992-11-27 | 1996-01-31 | Injectable composition |
US08/979,836 Expired - Lifetime US5977164A (en) | 1992-11-27 | 1997-11-26 | Stabilized pharmaceutical composition |
US09/028,906 Expired - Lifetime US5972992A (en) | 1992-11-27 | 1998-02-24 | Injectable composition |
US09/356,158 Expired - Fee Related US6140359A (en) | 1992-11-27 | 1999-07-19 | Injectable composition |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/970,558 Expired - Fee Related US6770670B2 (en) | 1992-11-27 | 2001-10-04 | Injectable composition |
US10/835,875 Abandoned US20040204479A1 (en) | 1992-11-27 | 2004-04-29 | Injectable composition |
Country Status (12)
Country | Link |
---|---|
US (7) | US5733888A (en) |
EP (4) | EP1384474A1 (en) |
JP (1) | JP2880292B2 (en) |
AT (2) | ATE169216T1 (en) |
AU (1) | AU5612694A (en) |
CA (2) | CA2149150C (en) |
DE (2) | DE69320206T2 (en) |
DK (2) | DK0835657T3 (en) |
ES (2) | ES2119996T3 (en) |
GR (1) | GR3027724T3 (en) |
PT (1) | PT835657E (en) |
WO (2) | WO1994012030A1 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030207936A1 (en) * | 2000-11-28 | 2003-11-06 | Hongming Chen | Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof |
US20030220391A1 (en) * | 2001-12-20 | 2003-11-27 | Bogardus Joseph Ballard | Pharmaceutical compositions of orally active taxane derivatives having enhanced bioavailability |
US20040092428A1 (en) * | 2001-11-27 | 2004-05-13 | Hongming Chen | Oral pharmaceuticals formulation comprising paclitaxel, derivatives and methods of administration thereof |
US20040204479A1 (en) * | 1992-11-27 | 2004-10-14 | David Carver | Injectable composition |
US20050016926A1 (en) * | 2003-07-24 | 2005-01-27 | Dabur Research Foundation | Stabilized formulation |
US20050142225A1 (en) * | 2002-06-10 | 2005-06-30 | Pliva-Lachema A.S. | Stabilised pharmaceutical compositions on the basis of polyoxyethlated castor oil and method for manufacturing the same |
JP2006143699A (en) * | 2004-11-24 | 2006-06-08 | Yung Shin Pharmaceutical Industry Co Ltd | Paclitaxel aqueous injection and method for preparing the same |
US20110038926A1 (en) * | 2002-06-26 | 2011-02-17 | Medigene Oncology Gmbh | Method of producing a cationic liposomal preparation comprising a lipophilic compound |
Families Citing this family (97)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW406020B (en) * | 1993-09-29 | 2000-09-21 | Bristol Myers Squibb Co | Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent |
FR2710534B1 (en) * | 1994-09-28 | 1996-07-05 | Bristol Myers Squibb Co | Stabilization solvent, pharmaceutical composition containing it, and process for its preparation. |
NL9500340A (en) * | 1995-02-22 | 1996-10-01 | Yew Tree Pharmaceuticals B V | Stabilized paclitaxel solution and pharmaceutical preparation containing said solution |
DE19536165A1 (en) * | 1995-09-28 | 1997-04-03 | Basf Ag | Process for cleaning alkoxylated fats |
US6245805B1 (en) * | 1995-10-26 | 2001-06-12 | Baker Norton Pharmaceuticals, Inc. | Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents |
US6964946B1 (en) * | 1995-10-26 | 2005-11-15 | Baker Norton Pharmaceuticals, Inc. | Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same |
US6395770B1 (en) | 1995-10-26 | 2002-05-28 | Baker Norton Pharmaceuticals, Inc. | Method and compositions for administering taxanes orally to human patients |
AU724842B2 (en) * | 1995-12-21 | 2000-09-28 | Genelabs Technologies, Inc. | Taxane composition and method |
US6515016B2 (en) | 1996-12-02 | 2003-02-04 | Angiotech Pharmaceuticals, Inc. | Composition and methods of paclitaxel for treating psoriasis |
US6495579B1 (en) | 1996-12-02 | 2002-12-17 | Angiotech Pharmaceuticals, Inc. | Method for treating multiple sclerosis |
US20030157187A1 (en) * | 1996-12-02 | 2003-08-21 | Angiotech Pharmaceuticals, Inc. | Compositions and methods for treating or preventing inflammatory diseases |
BR9713661A (en) | 1996-12-30 | 2000-10-24 | Battelle Memorial Institute | Formulation and method for the treatment of neoplasms by inhalation |
US20030087954A1 (en) * | 1997-01-07 | 2003-05-08 | Sonus Pharmaceuticals, Inc. | Method of treating bladder carcinoma using a Taxane/Tocopherol formulation |
US20030105156A1 (en) * | 1997-01-07 | 2003-06-05 | Nagesh Palepu | Method for administration of a taxane/tocopherol formulation to enhance taxane therapeutic utility |
US6458373B1 (en) * | 1997-01-07 | 2002-10-01 | Sonus Pharmaceuticals, Inc. | Emulsion vehicle for poorly soluble drugs |
US6727280B2 (en) * | 1997-01-07 | 2004-04-27 | Sonus Pharmaceuticals, Inc. | Method for treating colorectal carcinoma using a taxane/tocopherol formulation |
BE1011216A3 (en) * | 1997-06-13 | 1999-06-01 | Thissen En Abrege L T B Lab | Pharmaceutical form for the administration of paclitaxel, method of preparation of a composition paclitaxel ready to employment and use thereof. |
IL131217A0 (en) * | 1998-03-10 | 2001-01-28 | Napro Biotherapeutics Inc | Novel methods and compositions for delivery of taxanes |
US5922754A (en) * | 1998-10-02 | 1999-07-13 | Abbott Laboratories | Pharmaceutical compositions containing paclitaxel |
US6388112B1 (en) | 1998-10-20 | 2002-05-14 | Ben Venue Laboratories, Inc. | Process for purification of solvents useful in the preparation of pharmaceutical compositions |
US6071952A (en) * | 1998-12-02 | 2000-06-06 | Mylan Pharmaceuticals, Inc. | Stabilized injectable pharmaceutical compositions containing taxoid anti-neoplastic agents |
US6040330A (en) * | 1999-01-08 | 2000-03-21 | Bionumerik Pharmaceuticals, Inc. | Pharmaceutical formulations of taxanes |
US6410255B1 (en) * | 1999-05-05 | 2002-06-25 | Aurora Biosciences Corporation | Optical probes and assays |
ATE370928T1 (en) | 1999-05-14 | 2007-09-15 | Nereus Pharmaceuticals Inc | INTERLEUKIN-1 AND TUMOR NECROSIS FACTOR ALPHA MODULATORS, SYNTHESIS OF THESE MODULATORS AND METHODS OF APPLYING THESE MODULATORS |
DE19925211B4 (en) * | 1999-06-01 | 2006-01-12 | PBS Pharmaceutical Bulk Substances SA | Kit for the preparation of a formulation of paclitaxel |
EP1251845A1 (en) * | 2000-01-20 | 2002-10-30 | Baker Norton Pharmaceuticals, Inc. | Purifying polyoxyethylated castor oils with activated charcoal and pharmaceutical formulations thereof |
CZ20013498A3 (en) * | 2000-02-02 | 2002-04-17 | Florida State University Research Foundation, Inc. | Taxane formulations having enhanced solubility |
WO2001062919A1 (en) * | 2000-02-23 | 2001-08-30 | Aurora Biosciences Corporation | Modified fluorescent proteins |
US6951885B2 (en) | 2000-08-10 | 2005-10-04 | Takeda Pharmaceutical Company Limited | Pharmaceutical composition |
JP4922507B2 (en) * | 2000-08-10 | 2012-04-25 | 武田薬品工業株式会社 | Pharmaceutical composition |
US7144723B2 (en) * | 2000-11-16 | 2006-12-05 | The Regents Of The University Of California | Marine actinomycete taxon for drug and fermentation product discovery |
EP1379231A2 (en) | 2001-04-06 | 2004-01-14 | Cytorex Biosciences, Inc. | Pharmacologically active strong acid solutions |
KR100774366B1 (en) * | 2001-09-10 | 2007-11-08 | 주식회사 중외제약 | Injectable composition of paclitaxel |
EP1461056A4 (en) * | 2001-11-26 | 2006-01-25 | Supergen Inc | Method for preparing and using polyoxyethylated castor oil in pharmaceutical compositions |
US6476068B1 (en) * | 2001-12-06 | 2002-11-05 | Pharmacia Italia, S.P.A. | Platinum derivative pharmaceutical formulations |
US7176232B2 (en) | 2002-06-24 | 2007-02-13 | The Regents Of The University Of California | Salinosporamides and methods for use thereof |
CN100540548C (en) * | 2002-08-02 | 2009-09-16 | 尼瑞斯药品公司 | Synthesizing of dehydrophenylahistin and analogue thereof and dehydrophenylahistin and analogue thereof |
US7919497B2 (en) * | 2002-08-02 | 2011-04-05 | Nereus Pharmaceuticals, Inc. | Analogs of dehydrophenylahistins and their therapeutic use |
US7935704B2 (en) * | 2003-08-01 | 2011-05-03 | Nereus Pharmaceuticals, Inc. | Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof |
WO2004034970A2 (en) * | 2002-09-27 | 2004-04-29 | Nereus Pharmaceuticals, Inc. | Macrocyclic lactams |
EP1558241A2 (en) * | 2002-11-08 | 2005-08-03 | Bristol-Myers Squibb Company | Pharmaceutical compositions and methods of using taxane derivatives |
CA2515651A1 (en) * | 2003-02-11 | 2004-08-26 | Northwestern University | Methods and materials for nanocrystalline surface coatings and attachment of peptide amphiphile nanofibers thereon |
NZ544588A (en) * | 2003-06-20 | 2010-06-25 | Nereus Pharmaceuticals Inc | Use of salinosporamide A and analogs thereof for the treatment of cancer, inflammation and infectious diseases |
CN1823070A (en) * | 2003-06-20 | 2006-08-23 | 加利福尼亚大学董事会 | Salinosporamides and methods for use thereof |
US7619059B2 (en) * | 2003-07-29 | 2009-11-17 | Life Technologies Corporation | Bimolecular optical probes |
US7727752B2 (en) | 2003-07-29 | 2010-06-01 | Life Technologies Corporation | Kinase and phosphatase assays |
CA2445420A1 (en) * | 2003-07-29 | 2005-01-29 | Invitrogen Corporation | Kinase and phosphatase assays |
US20050208095A1 (en) * | 2003-11-20 | 2005-09-22 | Angiotech International Ag | Polymer compositions and methods for their use |
US7838551B2 (en) * | 2003-12-12 | 2010-11-23 | Quiral Quimica do Basil S.A. | Process for the preparation of concentrated, sterile injectable solutions containing docetaxel |
AU2005206560A1 (en) * | 2004-01-23 | 2005-08-04 | Nereus Pharmaceuticals, Inc. | Bis-indole pyrroles useful as antimicrobials agents |
KR20050099311A (en) * | 2004-04-09 | 2005-10-13 | 에이엔에이치 케어연구소(주) | Composition for injection comprising anticancer drug |
US7579371B2 (en) | 2004-04-30 | 2009-08-25 | Nereus Pharmaceuticals, Inc. | Methods of using [3.2.0] heterocyclic compounds and analogs thereof |
AU2005283141B2 (en) * | 2004-04-30 | 2012-05-10 | Nereus Pharmaceuticals, Inc. | (3.2.0) heterocyclic compounds and methods of using the same |
PL1830838T3 (en) * | 2004-12-03 | 2013-07-31 | Dana Farber Cancer Inst Inc | Compositions and methods for treating neoplastic diseases |
WO2006126825A1 (en) * | 2005-05-23 | 2006-11-30 | Choongwae Pharma Corporation | Composition comprising tetrafluorobenzyl derivatives or salts of thereof for injection |
KR20080030024A (en) * | 2005-06-17 | 2008-04-03 | 호스피라 오스트레일리아 피티와이 리미티드 | Liquid pharmaceutical formulations of docetaxel |
AU2006276274B2 (en) | 2005-07-21 | 2012-03-29 | Nereus Pharmaceuticals, Inc. | Interleukin-1 and tumor necrosis factor-a modulators; syntheses of such modulators and methods of using such modulators |
NZ566705A (en) | 2005-08-31 | 2011-06-30 | Abraxis Bioscience Llc | Compositions and methods for preparation of poorly water soluble drugs with increased stability |
ZA200802765B (en) | 2005-08-31 | 2009-08-26 | Abraxis Bioscience Llc | Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents |
BRPI0600194A (en) * | 2006-01-30 | 2007-10-23 | Quiral Quimica Do Brasil S A | docetaxel-containing pharmaceutical compositions and a degradation inhibitor and process for obtaining same |
US8129527B2 (en) * | 2006-11-03 | 2012-03-06 | Nereus Pharmacuticals, Inc. | Analogs of dehydrophenylahistins and their therapeutic use |
US7824698B2 (en) * | 2007-02-02 | 2010-11-02 | Nereus Pharmaceuticals, Inc. | Lyophilized formulations of Salinosporamide A |
FR2912745A1 (en) * | 2007-02-19 | 2008-08-22 | Centre Nat Rech Scient | NEW INDOLE-DERIVED COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
US20090017167A1 (en) * | 2007-07-11 | 2009-01-15 | Herbalife International Inc. | Mixture and beverage made therefrom for protecting cellular hydration |
US8394816B2 (en) * | 2007-12-07 | 2013-03-12 | Irene Ghobrial | Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's Macroglobulinemia |
KR101053780B1 (en) * | 2008-02-29 | 2011-08-02 | 동아제약주식회사 | Single liquid stable pharmaceutical composition containing docetaxel |
EP2276765A4 (en) * | 2008-05-12 | 2011-10-19 | Nereus Pharmaceuticals Inc | Salinosporamide derivatives as proteasome inhibitors |
ES2344674B1 (en) | 2008-08-07 | 2011-06-29 | Gp Pharm, S.A. | INJECTABLE PHARMACEUTICAL COMPOSITION OF TAXANOS. |
US9198968B2 (en) | 2008-09-15 | 2015-12-01 | The Spectranetics Corporation | Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens |
US8128951B2 (en) * | 2008-09-15 | 2012-03-06 | Cv Ingenuity Corp. | Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens |
US8257722B2 (en) | 2008-09-15 | 2012-09-04 | Cv Ingenuity Corp. | Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens |
US8114429B2 (en) | 2008-09-15 | 2012-02-14 | Cv Ingenuity Corp. | Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens |
TWI438009B (en) * | 2010-02-19 | 2014-05-21 | Teikoku Pharma Usa Inc | Taxane pro-emulsion formulations and methods making and using the same |
EP2566474B1 (en) | 2010-05-03 | 2017-11-15 | Teikoku Pharma USA, Inc. | Non-aqueous taxane pro-emulsion formulations and methods of making and using the same |
EP2691075A1 (en) | 2011-03-29 | 2014-02-05 | Sanofi | Otamixaban formulations with improved stability |
US20140234345A1 (en) * | 2011-07-11 | 2014-08-21 | Biolyse Pharma Corporation | Novel anti-cancer isocarbostyril alkaloid conjugates |
US9956385B2 (en) | 2012-06-28 | 2018-05-01 | The Spectranetics Corporation | Post-processing of a medical device to control morphology and mechanical properties |
JO3685B1 (en) | 2012-10-01 | 2020-08-27 | Teikoku Pharma Usa Inc | Non-aqueous taxane nanodispersion formulations and methods of using the same |
EP2777691A1 (en) | 2013-03-14 | 2014-09-17 | Pharmachemie B.V. | Taxoid - Purification of Liquid Excipients |
EP2968390A4 (en) * | 2013-03-15 | 2016-10-26 | Epizyme Inc | Injectable formulations for treating cancer |
US10525171B2 (en) | 2014-01-24 | 2020-01-07 | The Spectranetics Corporation | Coatings for medical devices |
CA2959965A1 (en) | 2014-09-02 | 2016-03-10 | Bhupinder Singh | Pharmaceutical formulations comprising tetrahydrocurcumin and lipids |
JP2017527567A (en) * | 2014-09-17 | 2017-09-21 | エピザイム インコーポレイテッド | Injection formulation for the treatment of cancer |
EP3204120B1 (en) | 2014-10-08 | 2021-05-26 | Pacific Northwest Research Institute | Methods and compositions for increasing the potency of antifungal agents |
RU2728796C2 (en) | 2015-03-06 | 2020-07-31 | Бейондспринг Фармасьютикалс, Инк. | Method for treating a brain tumor |
CN107530341B (en) | 2015-03-06 | 2021-10-01 | 大连万春布林医药有限公司 | Methods of treating cancers associated with RAS mutations |
SG10202108194XA (en) | 2015-07-13 | 2021-09-29 | Beyondspring Pharmaceuticals Inc | Plinabulin compositions |
US10561766B2 (en) * | 2015-09-15 | 2020-02-18 | W. L. Gore & Associates, Inc. | Drug composition and coating |
CA3013467A1 (en) | 2016-02-08 | 2017-08-17 | Beyondspring Pharmaceuticals, Inc. | Compositions containing tucaresol or its analogs |
BR112018074990A2 (en) | 2016-06-06 | 2019-03-12 | Beyondspring Pharmaceuticals, Inc. | composition, uses and method for reducing neutropenia |
US11633393B2 (en) | 2017-01-06 | 2023-04-25 | Beyondspring Pharmaceuticals, Inc. | Tubulin binding compounds and therapeutic use thereof |
EP3576733A4 (en) | 2017-02-01 | 2020-11-25 | Beyondspring Pharmaceuticals, Inc. | Method of reducing neutropenia |
US10226423B1 (en) * | 2017-12-20 | 2019-03-12 | RxOMEG Therapeutics LLC | Colchicine drug-to-drug interactions |
WO2019147615A1 (en) | 2018-01-24 | 2019-08-01 | Beyondspring Pharmaceuticals, Inc. | Composition and method for reducing thrombocytopenia via the administration of plinabulin |
EP3773612A4 (en) | 2018-03-28 | 2022-01-12 | Herbalife International of America, Inc. | Acetylation of polysaccharides |
JP2022508807A (en) * | 2018-10-16 | 2022-01-19 | ユーエス・ナノ・フード・アンド・ドラッグ・インコーポレーテッド | Intratumor injection product |
IL297015A (en) | 2020-04-13 | 2022-12-01 | US Nano Food & Drug INC | Basic chemotherapeutic intratumour injection formulation |
Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3864370A (en) | 1971-08-06 | 1975-02-04 | Ajinomoto Kk | Method of refining crude synthetic fatty acids |
US4814470A (en) | 1986-07-17 | 1989-03-21 | Rhone-Poulenc Sante | Taxol derivatives, their preparation and pharmaceutical compositions containing them |
US4942184A (en) | 1988-03-07 | 1990-07-17 | The United States Of America As Represented By The Department Of Health And Human Services | Water soluble, antineoplastic derivatives of taxol |
WO1990010443A1 (en) | 1989-03-09 | 1990-09-20 | University Of Kansas | Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof |
EP0428376A1 (en) | 1989-11-14 | 1991-05-22 | Florida State University | Method for preparation of taxol using an oxazinone |
EP0505047A1 (en) | 1991-03-18 | 1992-09-23 | Virginia Tech Intellectual Properties, Inc. | Rearranged taxol compounds and method of using in testing of in vivo activity |
US5157049A (en) | 1988-03-07 | 1992-10-20 | The United States Of America As Represented By The Department Of Health & Human Services | Method of treating cancers sensitive to treatment with water soluble derivatives of taxol |
EP0522936A1 (en) | 1991-07-08 | 1993-01-13 | Aventis Pharma S.A. | Taxane derivatives containing compositions |
US5254580A (en) | 1993-01-19 | 1993-10-19 | Bristol-Myers Squibb Company | 7,8-cyclopropataxanes |
US5281727A (en) | 1992-11-27 | 1994-01-25 | Napro Biotherapeutics, Inc. | Method of using ion exchange media to increase taxane yields |
WO1994012198A1 (en) | 1992-11-27 | 1994-06-09 | F.H. Faulding & Co. Limited | Injectable taxol composition |
US5391385A (en) | 1990-02-15 | 1995-02-21 | The Pq Corporation | Method of frying oil treatment using an alumina and amorphous silica composition |
US5504102A (en) | 1993-09-29 | 1996-04-02 | Bristol-Myers Squibb Company | Stabilized pharmaceutical composition and stabilizing solvent |
US5733388A (en) | 1994-08-11 | 1998-03-31 | Daido Tokiushuko Kabushiki Kaisha | Steel composition for bearings and method of producing the same |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2119996T3 (en) * | 1992-11-27 | 1998-10-16 | Napro Biotherapeutics Inc | INJECTABLE COMPOSITION INCLUDING FACLITAXEL. |
-
1993
- 1993-11-18 ES ES94901593T patent/ES2119996T3/en not_active Expired - Lifetime
- 1993-11-18 WO PCT/US1993/011199 patent/WO1994012030A1/en active Application Filing
- 1993-11-18 CA CA002149150A patent/CA2149150C/en not_active Expired - Lifetime
- 1993-11-18 EP EP03025151A patent/EP1384474A1/en active Pending
- 1993-11-18 EP EP97121710A patent/EP0835657B1/en not_active Revoked
- 1993-11-18 DE DE69320206T patent/DE69320206T2/en not_active Revoked
- 1993-11-18 EP EP94901593A patent/EP0674510B1/en not_active Revoked
- 1993-11-18 CA CA002308082A patent/CA2308082A1/en not_active Abandoned
- 1993-11-18 AU AU56126/94A patent/AU5612694A/en not_active Abandoned
- 1993-11-18 DE DE69333605T patent/DE69333605T2/en not_active Revoked
- 1993-11-18 AT AT94901593T patent/ATE169216T1/en not_active IP Right Cessation
- 1993-11-18 JP JP6513255A patent/JP2880292B2/en not_active Expired - Fee Related
- 1993-11-18 PT PT97121710T patent/PT835657E/en unknown
- 1993-11-18 AT AT97121710T patent/ATE274347T1/en not_active IP Right Cessation
- 1993-11-18 WO PCT/US1993/011209 patent/WO1994012031A1/en not_active Application Discontinuation
- 1993-11-18 DK DK97121710T patent/DK0835657T3/en active
- 1993-11-18 EP EP04020044A patent/EP1500393A1/en not_active Withdrawn
- 1993-11-18 DK DK94901593T patent/DK0674510T3/en active
- 1993-11-18 ES ES97121710T patent/ES2224200T3/en not_active Expired - Lifetime
-
1996
- 1996-01-31 US US08/594,478 patent/US5733888A/en not_active Expired - Lifetime
-
1997
- 1997-11-26 US US08/979,836 patent/US5977164A/en not_active Expired - Lifetime
-
1998
- 1998-02-24 US US09/028,906 patent/US5972992A/en not_active Expired - Lifetime
- 1998-08-26 GR GR980401904T patent/GR3027724T3/en unknown
-
1999
- 1999-07-19 US US09/356,158 patent/US6140359A/en not_active Expired - Fee Related
-
2000
- 2000-05-03 US US09/563,969 patent/US6306894B1/en not_active Expired - Fee Related
-
2001
- 2001-10-04 US US09/970,558 patent/US6770670B2/en not_active Expired - Fee Related
-
2004
- 2004-04-29 US US10/835,875 patent/US20040204479A1/en not_active Abandoned
Patent Citations (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3864370A (en) | 1971-08-06 | 1975-02-04 | Ajinomoto Kk | Method of refining crude synthetic fatty acids |
US4814470A (en) | 1986-07-17 | 1989-03-21 | Rhone-Poulenc Sante | Taxol derivatives, their preparation and pharmaceutical compositions containing them |
US4942184A (en) | 1988-03-07 | 1990-07-17 | The United States Of America As Represented By The Department Of Health And Human Services | Water soluble, antineoplastic derivatives of taxol |
US5157049A (en) | 1988-03-07 | 1992-10-20 | The United States Of America As Represented By The Department Of Health & Human Services | Method of treating cancers sensitive to treatment with water soluble derivatives of taxol |
WO1990010443A1 (en) | 1989-03-09 | 1990-09-20 | University Of Kansas | Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof |
US4960790A (en) | 1989-03-09 | 1990-10-02 | University Of Kansas | Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof |
EP0428376A1 (en) | 1989-11-14 | 1991-05-22 | Florida State University | Method for preparation of taxol using an oxazinone |
US5391385A (en) | 1990-02-15 | 1995-02-21 | The Pq Corporation | Method of frying oil treatment using an alumina and amorphous silica composition |
EP0505047A1 (en) | 1991-03-18 | 1992-09-23 | Virginia Tech Intellectual Properties, Inc. | Rearranged taxol compounds and method of using in testing of in vivo activity |
EP0522936A1 (en) | 1991-07-08 | 1993-01-13 | Aventis Pharma S.A. | Taxane derivatives containing compositions |
EP0522937A1 (en) | 1991-07-08 | 1993-01-13 | Aventis Pharma S.A. | Taxane derivatives containing compositions |
US5403858A (en) | 1991-07-08 | 1995-04-04 | Rhone-Poulenc Rorer, S.A. | New compositions containing taxane derivatives |
US5281727A (en) | 1992-11-27 | 1994-01-25 | Napro Biotherapeutics, Inc. | Method of using ion exchange media to increase taxane yields |
WO1994012198A1 (en) | 1992-11-27 | 1994-06-09 | F.H. Faulding & Co. Limited | Injectable taxol composition |
US5254580A (en) | 1993-01-19 | 1993-10-19 | Bristol-Myers Squibb Company | 7,8-cyclopropataxanes |
US5504102A (en) | 1993-09-29 | 1996-04-02 | Bristol-Myers Squibb Company | Stabilized pharmaceutical composition and stabilizing solvent |
US5733388A (en) | 1994-08-11 | 1998-03-31 | Daido Tokiushuko Kabushiki Kaisha | Steel composition for bearings and method of producing the same |
Non-Patent Citations (13)
Title |
---|
Dordunoo, Stephen K., and Helen M. Burt (1996) "Solubility and Stability of Taxol: Effects of Buffers and Cyclodextrins" International Journal of Pharmaceutics 133: 191-201. |
Kingston, David G. I. (1991) The Chemistry of Taxol: Pharmac. Ther. 52:1-34. |
Kingston, David G.I., Neal F. Magri, Chote Jitrangsri (1986) "Synthesis and Structure-Activity Relationships of Taxol Derivatives as Anticancer Agents" Studies in Organic Chemistry 26:219-235. |
Kingston, et al., "Synthesis and Structure-Activity Relationships of Taxol Derivatives as Anticancer Agents", Studies in Organic Chemistry 26:219-235, 1986.* |
Longnecker, et al. (1987) "High Performance Liquid Chromatographic Assay of Taxol in Human Plasma and Pharmacokitetics in Phase I Trial" Cancer Treatment Reports 71(1). |
Magri, Neal F. and David G. I. Kingston (1986) "Modified Taxols. 2. Oxidation Products of Taxol" Journal of Org. Chem. 51:797-802. |
Mathew, A. E. M. Mejillano, J. P. Nath, R. H. Himes, and V. J. Stella (1992) "Synthesis and Evaluation of Some Water Soluble Prodrugs and Derivat ives of Taxol and Antitumor Activity," J. Med. Chem. 35:145-51. |
Richheimer, Steven L., David M. Tinnermeier and Daniel W. Timmons (1992) "High Performance Liquid Chromatographic Assay of Taxol" Anal Chem. 64:2323-2326. |
Ringel, Israel, Susan Band Horwitz (1987) "Taxol is Converted to 7-Epitaxol, a Biologically Active isomer, in Cell Culture Medium" Journal of Pharmacology and Experimental therapeutics 242(1):692-698. |
Rowinsky, E., et al. "Taxol: A Novel Investigational Antimicrotubule Agent" Journal of the National Cancer Institute (1990) 82(15): 1247-59. |
Tarr, B. D. et al. "A New Parenteral Vehicle for the Administration of Some Poorly Soluble Anti-Cancer Drugs" J. Parenter. Sci. Technol. (1987) 41(1):31-33. |
Trissel, Lawrence (1988) "Monographs on Digoxin, Edrophonium chloride, Etoposide, Hydromorphine Hcl, Methyldopate HC1, Metronidazole, Nalbupine HC2, Phenylephjrine HCl, and Vitamin A" Handbook on Injectable Drugs, 5th Edition. |
Waugh, Wanda n., Lawrence A. Trissel and Valentino J. Stella (1991) "Stability, Compatibility, and Plasticizer Extraction of Taxol (NCS-125973) Injection Diluted in infusion Solutions and Stored in Various Containers" Reports Taxol 48 1520-1524. |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040204479A1 (en) * | 1992-11-27 | 2004-10-14 | David Carver | Injectable composition |
US6919370B2 (en) | 2000-11-28 | 2005-07-19 | Transform Pharmaceuticals, Inc. | Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof |
US20050191323A1 (en) * | 2000-11-28 | 2005-09-01 | Hongming Chen | Pharmaceutical formulations comprising paclitaxel, derivatives and pharmaceutically acceptable salts thereof |
US20030207936A1 (en) * | 2000-11-28 | 2003-11-06 | Hongming Chen | Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof |
US20040092428A1 (en) * | 2001-11-27 | 2004-05-13 | Hongming Chen | Oral pharmaceuticals formulation comprising paclitaxel, derivatives and methods of administration thereof |
US20030220391A1 (en) * | 2001-12-20 | 2003-11-27 | Bogardus Joseph Ballard | Pharmaceutical compositions of orally active taxane derivatives having enhanced bioavailability |
US20050142225A1 (en) * | 2002-06-10 | 2005-06-30 | Pliva-Lachema A.S. | Stabilised pharmaceutical compositions on the basis of polyoxyethlated castor oil and method for manufacturing the same |
US20110038926A1 (en) * | 2002-06-26 | 2011-02-17 | Medigene Oncology Gmbh | Method of producing a cationic liposomal preparation comprising a lipophilic compound |
US8075913B2 (en) | 2002-06-26 | 2011-12-13 | Medigene Ag | Method of producing a cationic liposomal preparation comprising a lipophilic compound |
US8663606B2 (en) | 2002-06-26 | 2014-03-04 | Medigene Ag | Method of producing a cationic liposomal preparation comprising a lipophilic compound |
US9238021B2 (en) | 2002-06-26 | 2016-01-19 | Medigene Ag | Method of producing a cationic liposomal preparation comprising a lipophilic compound |
US20060226076A1 (en) * | 2003-07-24 | 2006-10-12 | Dabur Research Foundation. | Stabilized formulation |
US7699987B2 (en) | 2003-07-24 | 2010-04-20 | Dabur Pharma Ltd. | Stabilized formulation |
US20050016926A1 (en) * | 2003-07-24 | 2005-01-27 | Dabur Research Foundation | Stabilized formulation |
JP2006143699A (en) * | 2004-11-24 | 2006-06-08 | Yung Shin Pharmaceutical Industry Co Ltd | Paclitaxel aqueous injection and method for preparing the same |
Also Published As
Publication number | Publication date |
---|---|
US6140359A (en) | 2000-10-31 |
CA2308082A1 (en) | 1994-06-09 |
EP0674510A1 (en) | 1995-10-04 |
DE69320206T2 (en) | 1999-02-11 |
DE69320206D1 (en) | 1998-09-10 |
ATE274347T1 (en) | 2004-09-15 |
US5733888A (en) | 1998-03-31 |
EP1384474A1 (en) | 2004-01-28 |
DE69333605D1 (en) | 2004-09-30 |
DE69333605T2 (en) | 2005-02-03 |
EP0835657A1 (en) | 1998-04-15 |
ES2224200T3 (en) | 2005-03-01 |
AU5612694A (en) | 1994-06-22 |
JPH08503945A (en) | 1996-04-30 |
US6770670B2 (en) | 2004-08-03 |
EP0835657B1 (en) | 2004-08-25 |
EP0674510A4 (en) | 1995-08-12 |
JP2880292B2 (en) | 1999-04-05 |
ATE169216T1 (en) | 1998-08-15 |
WO1994012030A1 (en) | 1994-06-09 |
GR3027724T3 (en) | 1998-11-30 |
US20030065022A1 (en) | 2003-04-03 |
US5977164A (en) | 1999-11-02 |
DK0835657T3 (en) | 2005-01-10 |
WO1994012031A1 (en) | 1994-06-09 |
ES2119996T3 (en) | 1998-10-16 |
PT835657E (en) | 2004-11-30 |
US5972992A (en) | 1999-10-26 |
CA2149150A1 (en) | 1994-06-09 |
US20040204479A1 (en) | 2004-10-14 |
EP1500393A1 (en) | 2005-01-26 |
DK0674510T3 (en) | 1999-05-10 |
CA2149150C (en) | 2000-08-01 |
EP0674510B1 (en) | 1998-08-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6306894B1 (en) | Injectable composition | |
KR100371062B1 (en) | Injectable taxi brush compositions with improved stability and methods of formulating them | |
AU614710B2 (en) | Stabilized drug compositions | |
CA1176567A (en) | Pharmaceutical preparation | |
JP4805599B2 (en) | Paclitaxel aqueous injection solution and preparation method thereof | |
JP2009524700A (en) | Pharmaceutical composition containing docetaxel and degradation inhibitor and method for producing the pharmaceutical composition | |
JP2006501134A (en) | Pharmaceutical composition of orally active taxane derivative having high bioavailability | |
AU2002351169B2 (en) | Method for preparing and using polyoxyethylated castor oil in pharmaceutical compositions | |
KR980008219A (en) | Pharmaceutical composition for stabilized injection | |
EP0452697A1 (en) | Stabilizer for 4-ethyl-2-hydroxyimino5-nitro-3-hexenamide-containing preparation and stabilizing method therefor | |
JPH0296534A (en) | Use of thromboxane antagonist in cyclosporin a induced renal toxity | |
RU2279873C2 (en) | Vinorelbin-containing oral pharmaceutical composition for soft capsule and method for treatment | |
JP2018115178A (en) | Docetaxel formulation | |
US20070082945A1 (en) | Discodermolide compositions | |
GB2388025A (en) | Kit for preparing a formulation of paclitaxel |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
CC | Certificate of correction | ||
AS | Assignment |
Owner name: MAYNE PHARMA (USA), INC., NEW JERSEY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NAPRO BIOTHERAPEUTICS, INC.;REEL/FRAME:015017/0022 Effective date: 20031212 |
|
REMI | Maintenance fee reminder mailed | ||
LAPS | Lapse for failure to pay maintenance fees | ||
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20051023 |